Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The US plasma fractionation market is seeing outstanding patterns that are molding its elements and impacting the healthcare industry. An apparent tendency is for the reemergence of demand for plasma-derived treatments, as the chronic illnesses for developing in parallel with the ever-rising incidence of infections. The importance of plasma fractionation which plays a crucial role in the different plasma protreatment products has increased as it allows an efficient separation of the basic compounds like antibodies, albumin, and coagulation factor out of the donated plasma.
Another critical pattern in the market is the developing awareness and acknowledgment of plasma-derived therapies among healthcare experts and patients. Plasma-derived items assume a fundamental part in dealing with conditions like immunodeficiency disorders, hemophilia, and autoimmune illnesses. As awareness about the viability of these therapies’ spreads, the demand for plasma fractionation is supposed to rise, adding to market growth.
As of late, advances in innovation and assembling processes have likewise affected the US plasma fractionation market. Developments in plasma fractionation strategies have prompted expanded productivity in the creation of plasma-derived items, considering a better return of therapeutic parts. These innovative progressions further develop the overall assembling process as well as add to cost-viability, making plasma-derived therapies more open to a more extensive patient population.
The Coronavirus pandemic significantly affects the US plasma fractionation market too. The requirement for improving plasma as a likely treatment for Coronavirus patients has expanded the demand for plasma and, thus, the plasma fractionation process. This excess in demand has provoked industry players to adjust and increase creation to meet the developing requirements of the healthcare framework.
US Plasma Fractionation Market Highlights:
US Plasma Fractionation Market Overview
US Plasma Fractionation Market Size was valued at USD 12.8 Billion in 2022. The US Plasma Fractionation market industry is projected to grow from USD13.76 billion in 2023 to USD 24.54 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.50% during the forecast period (2023 - 2032). Rising consumer awareness, changing eating habits, and the growing significance of US Plasma Fractionation for better health are the main market drivers anticipated to propel the US Plasma Fractionation market in the United States.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
US Plasma Fractionation Market Trends
-
Increasing demand for plasma-derived therapies is driving the market growth
A prominent trend in the US Plasma Fractionation market is the escalating demand for plasma-derived therapies. Plasma fractionation involves separating and processing blood plasma to extract specific proteins, which are then used to produce various therapeutic products. The rising prevalence of chronic diseases, autoimmune disorders, and genetic deficiencies has spurred the demand for plasma-derived therapies such as immunoglobulins, clotting factors, and albumin. These therapeutic products are crucial in treating conditions like haemophilia, immune deficiencies, and neurological disorders. The expanding application of plasma-derived therapies and their efficacy in managing a spectrum of medical conditions contribute to the sustained growth and innovation within the plasma fractionation market. This factor drives market CAGR.
Furthermore, another significant trend involves continuous technological advancements and an increased focus on quality assurance in plasma fractionation processes. Innovations in separation technologies, purification methods, and virus inactivation techniques are enhancing the efficiency and safety of plasma fractionation. The industry is investing in advanced technologies to ensure the production of high-quality plasma-derived products while adhering to stringent regulatory standards. Quality assurance measures, including virus screening and removal processes, are critical in safeguarding the safety of plasma-derived therapies. As the demand for plasma-derived products rises, the market trend emphasizes a commitment to technological advancements and rigorous quality control measures to meet the growing healthcare needs and ensure the safety and efficacy of plasma fractionation products in the US healthcare landscape.Thus driving the US Plasma Fractionation market revenue.
US Plasma Fractionation Market Segment Insights
US Plasma Fractionation Applications Insights
Based on Applications, the US Plasma Fractionation market segmentation includes Immunology, Hematology, and Others. Immunology is the dominant category in the US Plasma Fractionation market, primarily fueled by the increasing demand for immunoglobulins. Immunoglobulins, also known as antibodies, are crucial components derived from plasma and play a vital role in treating various autoimmune disorders, primary immunodeficiency diseases, and neurological conditions. The versatile applications of immunoglobulins in providing passive immunity and modulating the immune system contribute to their dominance in the plasma fractionation market. Additionally, haematology is the fastest-growing category in the US plasma filtration market, propelled by advancements in clotting factor therapies. Plasma fractionation is crucial in extracting clotting factors for treating haemophilia, von Willebrand disease, and other bleeding disorders. Ongoing innovations in clotting factor concentrates, improved purification techniques, and personalized treatment approaches drive the rapid growth in haematology applications.
Figure1:U.S. Plasma Fractionation Market, by Applications, 2022 & 2032(USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
US Plasma Fractionation Product Types Insights
Based on Product Types, the US Plasma Fractionation market segmentation includes Albumin, Immune Globulin, Coagulation Factor, and Others. Immune Globulin (I.G.) products emerge as the dominant category in the US Plasma Fractionation market, owing to their wide therapeutic applications and increasing demand. I.G. products derived from plasma are crucial in treating various autoimmune disorders, immunodeficiency conditions, and neurological disorders. The versatility of I.G. in providing passive immunity, modulating the immune system, and managing chronic conditions positions it as a cornerstone in the plasma fractionation market. Additionally, the fastest-growing category in the US plasma filtration market is coagulation factor products, driven by advancements in haematology and bleeding disorder treatments. Coagulation factors extracted through plasma fractionation are critical in treating conditions such as haemophilia and von Willebrand disease. Ongoing innovations in clotting factor concentrates, purification technologies, and personalized treatment approaches are propelling the rapid growth of Coagulation Factor products.
US Plasma Fractionation Country Insights
In the United States, the Plasma Fractionation market reflects a robust and dynamic landscape driven by the growing demand for plasma-derived therapies. Immunoglobulins, dominating the market, cater to diverse immunological disorders, showcasing the crucial role of plasma fractionation in treating autoimmune and immunodeficiency conditions. Concurrently, advancements in clotting factor therapies drive the rapid growth of haematology applications, meeting the evolving therapeutic needs of patients with bleeding disorders. The market's focus on Immune Globulin products underscores their versatility, while the surge in Coagulation Factor products highlights the commitment to advancing haematology treatments. With increasing awareness, technological innovations, and a broad spectrum of therapeutic applications, the US Plasma Fractionation market stands at the forefront of providing essential and tailored therapies for various medical conditions.
US Plasma Fractionation Key Market Players & Competitive Insights
Prominent industry participants are making significant investments in R&D to broaden their product offerings, contributing to the further expansion of the US Plasma Fractionation market. In addition, market participants are engaging in a range of strategic endeavors aimed at broadening their market reach. Notable events in this regard include the introduction of new products, contractual agreements, mergers and acquisitions, increased investment levels, and cooperation with other entities. In order to grow and thrive in a more competitive and rising market environment, the US Plasma Fractionation business needs to provide affordable products.
Major players in theUS Plasma Fractionationmarket are attempting to increase market demand by investing in research and development operations, including Takeda, CSL, rifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO.
Key Companies in the US Plasma Fractionation market include
US Plasma Fractionation Industry Developments
April 2023:CSL (Australia) received Food and Drug Administration (FDA) approval for the 50mL/10gm prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid for patients suffering from P.I. and CIPD.
March 2022:Grifols (Spain) received European approvals for XEMBIFY, a 20% subcutaneous immunoglobulin (SCIG).
US Plasma Fractionation Market Segmentation
US Plasma Fractionation Applications Outlook
- Immunology
- Haematology
- Others
US Plasma Fractionation Product Types Outlook
- Albumin
- Immune Globulin
- Coagulation Factor
- Others
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
